Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.43 |
| ▸ | SCN4A | P35499 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3715951 | 1.00 | LMNA (0.52) | LMNAADRA2AADRA2CHIF1AKDM4E | |
| SCHEMBL2781359 | 0.84 | DPP4 (0.55) | TAAR1SCN4A | |
| SCHEMBL2781356 | 0.84 | DPP4 (0.55) | TAAR1SCN4A | |
| SCHEMBL2784864 | 0.84 | DPP4 (0.55) | TAAR1SCN4A | |
| SCHEMBL13619701 | 0.83 | TAAR1 (0.46) | LMNAADRA2AADRA2CHIF1AKDM4E | |
| SCHEMBL13996063 | 0.83 | TAAR1 (0.46) | LMNAADRA2AADRA2CHIF1AKDM4E | |
| SCHEMBL26236051 | 0.81 | TAAR1 (0.56) | TAAR1AOC3SCN4A | |
| SCHEMBL3651367 | 0.81 | LMNA (0.54) | LMNAADRA2AADRA2CHIF1AKDM4E | |
| SCHEMBL27587669 | 0.80 | HRH1 (0.50) | LMNAADRA2AADRA2CHIF1AKDM4E | |
| Hydrochloric Acid SCHEMBL15372828 | 0.79 | APAF1 (0.50) | LMNAADRA2AADRA2CHIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311798-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | HOFFMANN-LA ROCHE, INC. | 2010-12-09 | — | — | US | disclosed |
| WO-2010139707-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311798-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | LMNA 3672/4885ADRA2A 83/4885ADRA2C 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.